ORNBVH Stock Overview
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Orion Oyj Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €36.54 |
52 Week High | €46.09 |
52 Week Low | €36.52 |
Beta | 0.35 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -19.99% |
3 Year Change | 6.97% |
5 Year Change | 11.37% |
Change since IPO | 139.61% |
Recent News & Updates
Recent updates
Shareholder Returns
ORNBVH | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0% | 1.7% | 1.0% |
1Y | -20.0% | 5.2% | 3.0% |
Return vs Industry: ORNBVH underperformed the UK Pharmaceuticals industry which returned -1.6% over the past year.
Return vs Market: ORNBVH underperformed the UK Market which returned -3.9% over the past year.
Price Volatility
ORNBVH volatility | |
---|---|
ORNBVH Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ORNBVH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ORNBVH's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1917 | 3,632 | Liisa Hurme | www.orion.fi |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson’s disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
ORNBVH fundamental statistics | |
---|---|
Market cap | €5.40b |
Earnings (TTM) | €216.80m |
Revenue (TTM) | €1.19b |
24.9x
P/E Ratio4.5x
P/S RatioIs ORNBVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ORNBVH income statement (TTM) | |
---|---|
Revenue | €1.19b |
Cost of Revenue | €531.90m |
Gross Profit | €657.80m |
Other Expenses | €441.00m |
Earnings | €216.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 1.54 |
Gross Margin | 55.29% |
Net Profit Margin | 18.22% |
Debt/Equity Ratio | 22.5% |
How did ORNBVH perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield105%
Payout RatioDoes ORNBVH pay a reliable dividends?
See ORNBVH dividend history and benchmarksOrion Oyj dividend dates | |
---|---|
Ex Dividend Date | Mar 21 2024 |
Dividend Pay Date | Apr 03 2024 |
Days until Ex dividend | 44 days |
Days until Dividend pay date | 31 days |
Does ORNBVH pay a reliable dividends?
See ORNBVH dividend history and benchmarks